DARPA is offering the Panacea grant aimed at addressing human physiology limitations in the Department of Defense. This grant seeks to develop new technological approaches in medicinal chemistry to expand the druggable proteome, focusing on soft tissue pain/inflammation and metabolic stress. The goal is to discover therapeutic tools that can support the optimal physiological function of warfighters. Researchers are encouraged to propose innovative solutions that will advance drug discovery and development pipelines. The closing date for applications is February 22, 2019.
Opportunity ID: 310972
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HR001119S0010 |
| Funding Opportunity Title: | Panacea |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Other Procurement Contract |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 12.910 — Research and Technology Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Dec 10, 2018 |
| Last Updated Date: | Dec 10, 2018 |
| Original Closing Date for Applications: | Feb 22, 2019 See Full Announcement for details. |
| Current Closing Date for Applications: | Feb 22, 2019 See Full Announcement for details. |
| Archive Date: | Mar 24, 2019 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | All responsible sources capable of satisfying the Government’s needs may submit a proposal that shall be considered by DARPA. See the Eligibility Information section of the BAA for more information. |
Additional Information
| Agency Name: | DARPA – Biological Technologies Office |
| Description: | Human physiology is a limiting factor in the operational readiness of the United States Department of Defense. When the human body is damaged or a physiological system is not functioning optimally, interventions are required to help mend the injury or support continued performance. DARPA seeks to develop new technological approaches in medicinal chemistry and systems pharmacology to expand the druggable proteome and discover new therapeutic tools in the areas of soft tissue pain/inflammation and metabolic stress that limit optimal physiological function.. This new platform technology will directly address needs within the Department of Defense to support the unique physiological demands of the warfighter and provide proof-of-concept for novel drug discovery and development pipelines. |
| Link to Additional Information: | FedBizOpps Announcement |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
BAA Coordinator
Panacea@darpa.mil Email:Panacea@darpa.mil |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 310972 Full Announcement-HR001119S0010 -> HR001119S0010.pdf
Folder 310972 Full Announcement-HR001119S0010 -> Attachment 1 – HR00119S0010 – Summary Slide Template.pdf
Folder 310972 Full Announcement-HR001119S0010 -> Attachment 2 – HR00119S0010 – Budget Template.pdf
Packages
| Agency Contact Information: | BAA Coordinator Panacea@darpa.mil Email: Panacea@darpa.mil |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.910 | PKG00246790 | Dec 10, 2018 | Feb 22, 2019 | View |
Package 1
Mandatory forms
310972 RR_SF424_2_0-2.0.pdf
310972 AttachmentForm_1_2-1.2.pdf
310972 RR_KeyPersonExpanded_2_0-2.0.pdf
310972 RR_PersonalData_1_2-1.2.pdf
Optional forms
310972 SFLLL_1_2-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
